Q&A With Jay Edelberg From Sanofi: Answering More Questions Since PCSK9 Approval

December 10, 2015
Adam Hochron

It was not that long ago that PCSK9 inhibitors were just an idea being discussed in the field of cardiology. Just a few months ago the FDA approved the first treatments which has meant answers to many questions with some questions still remaining.

It was not that long ago that PCSK9 inhibitors were just an idea being discussed in the field of cardiology. Just a few months ago the FDA approved the first treatments which has meant answers to many questions with some questions still remaining.

Jay Edelberg, MD, PhD, from Sanofi discussed how far the field has come in recent years, what it has meant to patient care so far, and what work remains to be done during the annual scientific sessions of the American Heart Association in Orlando.